- Home
- AIFA vs HIND Comparison
AIFA vs HIND Comparison
Compare AIFA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIFA | HIND |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 15.2M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AIFA | HIND |
|---|---|---|
| Price | $3.17 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 439.9K | 6.1K |
| Earning Date | N/A | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,655,039.00 | $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.50 | ★ 24.43 |
| 52 Week Low | $1.52 | $1.75 |
| 52 Week High | $3.45 | $9.56 |
Technical Indicators
Market Signals| Indicator | AIFA | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 50.96 |
| Support Level | $2.72 | $1.99 |
| Resistance Level | $3.40 | $2.35 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 54.41 | 31.31 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.